Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), an innovative Israeli oncology company, has announced that CEO Uzi Sofer and CFO Raphi Levy will present at the J.P. Morgan 2026 Healthcare Conference on January 15, 2026. Their presentation is scheduled for 11:15 AM PT / 2:15 PM ET at the Westin St. Francis in San Francisco, CA. This event will also include one-on-one meetings for institutional investors interested in learning more about the company and its revolutionary cancer therapy, Alpha DaRT®.

Founded in 2016, Alpha Tau specializes in the research and development of Alpha DaRT, a pioneering treatment designed for solid tumors. The technology stems from the work of Professors Itzhak Kelson and Yona Keisari at Tel Aviv University. Alpha DaRT utilizes Diffusing Alpha-emitters Radiation Therapy, which allows for the precise intratumoral delivery of radium-224 sources. The radiation emitted from the decaying radium targets cancer cells with short-range high-energy alpha particles, aiming to destroy tumor tissue while minimizing damage to surrounding healthy cells.

The upcoming presentation at the J.P. Morgan conference marks a significant opportunity for Alpha Tau to showcase its advancements and future plans, as well as engage with potential investors about its innovative approach to oncology. Interested parties can access the presentation via a webcast link to be provided on the company's Investor Relations page.

For further inquiries or to schedule meetings with the executives, interested investors are encouraged to reach out to their J.P. Morgan representatives. As Alpha Tau prepares for this critical engagement within the healthcare investment community, the company continues to push the boundaries of cancer treatment technology.

As Alpha Tau Medical Ltd. prepares to present at the prestigious J.P. Morgan 2026 Healthcare Conference, investor attention is focused on the company's innovative approach to cancer therapy through its Alpha DaRT® technology. Founded in 2016, Alpha Tau is at the forefront of oncology therapeutics, leveraging its unique alpha-radiation cancer treatment aimed at solid tumors. Scheduled for January 15, 2026, the presentation by CEO Uzi Sofer and CFO Raphi Levy will be critical in showcasing the company’s advancements and strategic vision to institutional investors.

Market participants should consider a few key factors when evaluating Alpha Tau’s potential. First, the ongoing development of the Alpha DaRT technology, which offers targeted cancer treatment while minimizing damage to surrounding healthy tissues, positions the company advantageously in the competitive oncology landscape. The effectiveness of alpha-radiation in destroying tumors stands out as a promising area of growth, particularly as evidence from clinical trials continues to accumulate.

Secondly, the timing of this presentation coincides with increasing investor interest in innovative healthcare solutions, particularly in oncology, where demand for novel therapies is robust. Preparing for the conference, investors should analyze Alpha Tau’s most recent clinical data and milestones, as these will be focal points of the discussion. Positive results could catalyze market sentiment and drive share price appreciation, while any setbacks might present a risk.

Finally, institutional investor meetings, a crucial component of the event, provide an opportunity for in-depth engagement with the company’s leadership. Investors should be alert to the narratives that emerge during these discussions, as they often lend insight into the company’s trajectory and competitive positioning.

In summary, Alpha Tau’s upcoming presentation presents a unique opportunity for investors. Monitoring clinical outcomes and strategic updates while gauging investor sentiment post-presentation could inform more nuanced investment decisions in the dynamic healthcare sector.